Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 22,000 shares, a decline of 18.2% from the November 15th total of 26,900 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.7% of the company’s shares are sold short.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright lifted their price objective on Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Insiders Place Their Bets

In other news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company’s stock in a transaction on Monday, October 28th. The stock was bought at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at $25,187.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 34.90% of the stock is owned by insiders.

Monopar Therapeutics Stock Up 4.7 %

Shares of MNPR stock traded up $1.13 on Friday, hitting $25.38. The stock had a trading volume of 47,461 shares, compared to its average volume of 638,553. The business has a 50 day moving average price of $15.94 and a 200 day moving average price of $7.83. The company has a market cap of $133.96 million, a PE ratio of -12.88 and a beta of 1.23. Monopar Therapeutics has a one year low of $1.40 and a one year high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Equities research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.